Single-Domain Antibodies for Targeting, Detection, and


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 22 10 2021
accepted: 17 11 2021
entrez: 27 12 2021
pubmed: 28 12 2021
medline: 15 2 2022
Statut: epublish

Résumé

The advancement of new immunotherapies necessitates appropriate probes to monitor the presence and distribution of distinct immune cell populations. Considering the key role of CD4

Identifiants

pubmed: 34956237
doi: 10.3389/fimmu.2021.799910
pmc: PMC8696186
doi:

Substances chimiques

Single-Domain Antibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

799910

Informations de copyright

Copyright © 2021 Traenkle, Kaiser, Pezzana, Richardson, Gramlich, Wagner, Seyfried, Weldle, Holz, Parfyonova, Nueske, Scholz, Zeck, Jakobi, Schneiderhan-Marra, Schaller, Maurer, Gouttefangeas, Kneilling, Pichler, Sonanini and Rothbauer.

Déclaration de conflit d'intérêts

DSo, MK, BP, BT, PK, and UR are named as inventors on a patent application claiming the use of the described nanobodies for diagnosis and therapeutics filed by the Natural and Medical Sciences Institute and the Werner Siemens Imaging Center. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Immunol Rev. 1983;74:29-56
pubmed: 6195085
Clin Chem. 1981 Mar;27(3):493-501
pubmed: 7471403
Cancer Immunol Immunother. 2007 Mar;56(3):303-317
pubmed: 16738850
Nucl Med Biol. 2014 Apr;41(4):350-4
pubmed: 24503329
Cancer Gene Ther. 2021 Feb;28(1-2):5-17
pubmed: 32457487
J Nucl Med. 2015 Aug;56(8):1258-64
pubmed: 25952734
Mol Pharm. 2021 Mar 1;18(3):1317-1326
pubmed: 33506680
Cytometry A. 2019 Jun;95(6):647-654
pubmed: 30714682
Arthritis Rheum. 1995 Nov;38(11):1581-8
pubmed: 7488278
Trends Biotechnol. 2018 Jul;36(7):649-652
pubmed: 29395345
Blood. 2009 Jul 9;114(2):328-37
pubmed: 19417212
Front Oncol. 2020 Jul 23;10:1182
pubmed: 32793488
Nature. 1993 Jun 3;363(6428):446-8
pubmed: 8502296
Eur J Nucl Med. 1990;17(3-4):156-9
pubmed: 2149102
Sci Rep. 2015 Aug 21;5:13402
pubmed: 26292717
J Nucl Med. 2013 May;54(5):776-84
pubmed: 23487015
Front Immunol. 2021 Mar 09;12:632687
pubmed: 33767701
J Exp Med. 2017 Aug 7;214(8):2243-2255
pubmed: 28666979
Biomark Insights. 2010 Feb 09;5:9-20
pubmed: 20212918
Nat Rev Immunol. 2009 Jun;9(6):393-407
pubmed: 19444307
Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):14181-14190
pubmed: 31068469
J Immunol. 1991 May 1;146(9):2928-34
pubmed: 1673145
EMBO J. 1993 Apr;12(4):1547-53
pubmed: 8467804
J Immunol Methods. 2008 Jan 1;329(1-2):21-30
pubmed: 17964595
Cancers (Basel). 2021 Jan 20;13(3):
pubmed: 33498483
Biomed Hub. 2017 Nov 21;2(Suppl 1):79-86
pubmed: 31988938
J Nucl Med. 2005 Oct;46(10):1696-700
pubmed: 16204720
Cell Rep. 2019 Jul 16;28(3):819-831.e4
pubmed: 31315057
Cancer Commun (Lond). 2019 Jun 14;39(1):34
pubmed: 31200766
Mol Imaging Biol. 2018 Apr;20(2):260-267
pubmed: 28875290
J Biol Chem. 2009 Jan 30;284(5):3273-3284
pubmed: 19010777
Mol Imaging Biol. 2008 May-Jun;10(3):167-75
pubmed: 18297364
Nature. 1997 May 29;387(6632):527-30
pubmed: 9168119
Theranostics. 2017 Aug 11;7(14):3398-3414
pubmed: 28912884
Theranostics. 2014 Apr 25;4(7):708-20
pubmed: 24883121
Clin Cancer Res. 2017 Nov 1;23(21):6616-6628
pubmed: 28751451
Cancer Sci. 2009 Dec;100(12):2444-50
pubmed: 19775286
Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6444-8
pubmed: 7604010
Science. 2015 Jan 16;347(6219):278-82
pubmed: 25593185
Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11399-404
pubmed: 21697512
Contrast Media Mol Imaging. 2014 May-Jun;9(3):211-20
pubmed: 24700748
J Immunol. 1983 Nov;131(5):2178-83
pubmed: 6195255
Mol Cancer Ther. 2008 Aug;7(8):2288-97
pubmed: 18723476
Theranostics. 2014 Jan 29;4(4):386-98
pubmed: 24578722
J Nucl Med. 2015 Aug;56(8):1265-71
pubmed: 26069306
MAbs. 2019 Feb/Mar;11(2):239-264
pubmed: 30543482
Proc Natl Acad Sci U S A. 2016 May 17;113(20):5682-7
pubmed: 27114505
EMBO Rep. 2021 May 5;22(5):e52325
pubmed: 33904225
Vet Immunol Immunopathol. 2009 Mar 15;128(1-3):178-83
pubmed: 19026455
J Immunol. 1999 Feb 1;162(3):1431-9
pubmed: 9973399
Theranostics. 2019 Oct 18;9(26):8221-8238
pubmed: 31754392
Angew Chem Int Ed Engl. 2011 May 23;50(22):5024-32
pubmed: 21538739
Nat Methods. 2019 Jul;16(7):595-602
pubmed: 31249422
Rheumatology (Oxford). 2002 Oct;41(10):1142-8
pubmed: 12364634
Theranostics. 2019 Oct 15;9(25):7772-7791
pubmed: 31695800
Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21182-7
pubmed: 22160724
Antibodies (Basel). 2019 Jan 21;8(1):
pubmed: 31544819
Nat Commun. 2021 Feb 19;12(1):1152
pubmed: 33608538
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4025-4030
pubmed: 30765520
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7460-3
pubmed: 8755495
Theranostics. 2020 Jan 1;10(2):938-955
pubmed: 31903161
Nat Commun. 2018 Mar 2;9(1):930
pubmed: 29500346
Mol Cell Proteomics. 2008 Feb;7(2):282-9
pubmed: 17951627
Contrast Media Mol Imaging. 2016 Sep;11(5):328-339
pubmed: 27147480
J Am Soc Mass Spectrom. 2018 Mar;29(3):623-629
pubmed: 29299838
Mol Imaging Biol. 2017 Aug;19(4):599-609
pubmed: 27966069
Sci Rep. 2016 Jan 21;6:19211
pubmed: 26791954
Methods Mol Biol. 2018;1764:153-171
pubmed: 29605914
Mol Cell Proteomics. 2015 Mar;14(3):707-23
pubmed: 25595278
J Immunol. 1987 Nov 15;139(10):3207-12
pubmed: 2960730
J Immunother Cancer. 2017 Apr 18;5:33
pubmed: 28428882
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
Int Rev Neurobiol. 2007;79:43-72
pubmed: 17531837
NPJ Syst Biol Appl. 2018 Feb 6;4:9
pubmed: 29423275
Contrast Media Mol Imaging. 2011 Mar-Apr;6(2):85-92
pubmed: 20936711
Science. 2016 Oct 14;354(6309):197-202
pubmed: 27738167
Int J Cancer. 2012 Jul 1;131(1):140-9
pubmed: 21858810
Front Immunol. 2019 Nov 19;10:2526
pubmed: 31803175
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
J Virol. 1990 Sep;64(9):4468-76
pubmed: 2200889
J Nucl Med. 2016 Jan;57(1):27-33
pubmed: 26449837
FEBS Lett. 1997 Sep 15;414(3):521-6
pubmed: 9323027

Auteurs

Bjoern Traenkle (B)

NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.

Philipp D Kaiser (PD)

NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.

Stefania Pezzana (S)

Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tübingen, Tübingen, Germany.

Jennifer Richardson (J)

Department of Immunology, Institute of Cell Biology, University of Tübingen, Tübingen, Germany.

Marius Gramlich (M)

NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.

Teresa R Wagner (TR)

NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Pharmaceutical Biotechnology, University of Tübingen, Tübingen, Germany.

Dominik Seyfried (D)

Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tübingen, Tübingen, Germany.
German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) partner site Tübingen, Tübingen, Germany.

Melissa Weldle (M)

Pharmaceutical Biotechnology, University of Tübingen, Tübingen, Germany.

Stefanie Holz (S)

Pharmaceutical Biotechnology, University of Tübingen, Tübingen, Germany.

Yana Parfyonova (Y)

Pharmaceutical Biotechnology, University of Tübingen, Tübingen, Germany.

Stefan Nueske (S)

Livestock Center of the Faculty of Veterinary Medicine, Ludwig Maximilians University Munich, Oberschleissheim, Germany.

Armin M Scholz (AM)

Livestock Center of the Faculty of Veterinary Medicine, Ludwig Maximilians University Munich, Oberschleissheim, Germany.

Anne Zeck (A)

NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.

Meike Jakobi (M)

NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.

Nicole Schneiderhan-Marra (N)

NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.

Martin Schaller (M)

Department of Dermatology, University of Tübingen, Tübingen, Germany.

Andreas Maurer (A)

Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies," University of Tübingen, Tübingen, Germany.

Cécile Gouttefangeas (C)

Department of Immunology, Institute of Cell Biology, University of Tübingen, Tübingen, Germany.
German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) partner site Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies," University of Tübingen, Tübingen, Germany.

Manfred Kneilling (M)

Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tübingen, Tübingen, Germany.
Department of Dermatology, University of Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies," University of Tübingen, Tübingen, Germany.

Bernd J Pichler (BJ)

Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tübingen, Tübingen, Germany.
German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) partner site Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies," University of Tübingen, Tübingen, Germany.

Dominik Sonanini (D)

Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tübingen, Tübingen, Germany.
Department of Medical Oncology and Pneumology, University of Tübingen, Tübingen, Germany.

Ulrich Rothbauer (U)

NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Pharmaceutical Biotechnology, University of Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies," University of Tübingen, Tübingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH